Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world
Published By : Prameya News Bureau | August 21, 2021 IST
Share
Ahmedabad, Aug 21: Zydus Cadila today announced that the company has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day. With this approval, India now has its first COVID-19 vaccine for adolescents in the 12-18 age group, besides the adult population. ZyCoV-D, is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery. This is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use. The platform because of its rapid plug and play technology can be easily adapted to deal with mutations in the virus, such as those already occurring. The company plans to manufacture 10-12 crore doses of ZyCoV-D annually. Speaking on this development, Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said “This is a historic milestone with ZyCoV-D, a product of Indian innovation becoming the world’s first DNA vaccine being offered for human use and supporting the world’s largest immunization drive. We are particularly happy that our vaccine will contribute to this fight against COVID-19 and enable the country to vaccinate a larger population especially in the age group of 12-18 years. I would like to thank all the researchers, clinical trial investigators, volunteers and the regulators who have supported this endeavour.” The company also plans to seek approval for the two dose regimen of the vaccine.The main advantage of DNA vaccines is their ability to stimulate both the humoral and cellular arms of the adaptive immune system. They are a valuable form of antigen-specific immunotherapy, as they are safe, stable and can be easily produced. Zydus acknowledges the support of National Biopharma Mission, BIRAC, Department of Biotechnology, Govt of India, National Institute of Virology, Indian Council of Medical Research and PharmaJet® in the development of ZyCoV-D vaccine.
News7 Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
Lawyers write to CJI over group trying to ‘pressurise judiciary’
Delhi horror: 5-year-old kidnapped, raped & killed; accused held
LS polls: 2.54 crore voters for Phase 1 in Rajasthan; 13 above 120 years of age
Big shock for BRS as Hyderabad Mayor decides to join Congress
Nominations for 2nd phase begins in 13 Raj Seats
Government hikes wages of MGNREGA job card holders
NITA Football Academy emerges victorious in IWL-2 encounter
Arunachal was, is, and will remain an integral part of India: MEA
Govinda joins Shiv Sena in CM Shinde's presence; may be fielded from Mumbai North West
‘To browbeat and bully others is vintage Congress culture', says PM Modi on lawyers’ letter to CJI
Jhunjhunu LS constituency tops charts with highest centenarian women voters in Rajasthan
Excise policy case: Delhi court extends CM Kejriwal's ED custody till April 1
Heatwave conditions in Gujarat as several cities record around 40 degrees temperature
Sensex crosses 74K mark in 1000 points rally
Political conspiracy, claims Kejriwal while being taken to Rouse Avenue Court
Ladakh agitation intensifies as protesters threaten march to border with China
CM Kejriwal to be produced before Delhi court today as 6-day ED custody ends
Nobel-winning economist Daniel Kahneman dies at 90
Fresh petition filed in UP court to declare Taj Mahal as Shiva temple
BJP appoints election in-charges, co-incharges for states, UTs